{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination induces an interferon-linked tumor state and broadens antigen presentation pathways.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems, so magnitude and consistency may vary across contexts."
    },
    {
      "claim_id": "C02",
      "claim": "The therapeutic rationale is specifically for combining intratumoral mRNA vaccination with checkpoint blockade rather than either monotherapy alone.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "- Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
          "line_ref": "L36"
        },
        {
          "quote": "- ICI-only treatment had limited activity in low-immunogenic baseline settings.",
          "line_ref": "L37"
        }
      ],
      "caveat": "Mouse efficacy may not translate directly to all human tumors, and control performance can depend on baseline tumor immunogenicity."
    },
    {
      "claim_id": "C03",
      "claim": "In metastatic patients receiving ICI, prior SARS-CoV-2 mRNA vaccination status was associated with better survival outcomes.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        }
      ],
      "caveat": "Because the human cohort is retrospective and non-randomized with heterogeneous timing and histories, this supports association rather than definitive causality."
    },
    {
      "claim_id": "C04",
      "claim": "Observed sensitization depends on mRNA cargo and intact type I interferon signaling, based on perturbation controls.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "- Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        },
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "These controls support mechanism in tested systems, but pathway dependence may differ across tumor types and clinical settings."
    }
  ]
}